The clinical and pathological features of 51 patients who survived for more than 20 years after diagnosis of cancer of the breast were compared with those of 176 contemporaries who died within 20 years after diagnosis. Of those who survived, 18 (35%) had had pathologically affected axillary nodes compared with at least 86 (49%) of those who died. Also, 11 (21%) of the survivors had had small tumours compared with 10 (6%) of those who died. Pathological review of tumours in the survivors showed 40 (78%) to have been infiltrating ductal carcinomas, of which 13 (32%) were grade 3 lesions.
Introduction
Cancer of the breast, unlike many other forms of cancer, may recur or result in metastasis decades after the original diagnosis and treatment. Brinkley and Haybittle have, however, shown that the subgroup of women who remain free from the disease for 20 years after treatment have a subsequent survival that is similar to that of a normal population matched for age. 1 This suggests that the disease has been eradicated in most patients within this group. Nevertheless, despite the survival curves being apparently parallel, the women in the "cured" cohort still have a greatly increased risk of dying of breast cancer when compared with the normal population.
We analysed the records of all patients with clinically nondisseminated invasive cancer of the breast at first presentation who had received their primary treatment from this unit before 31 December 1961. Complete follow up was available for all these patients. Information was sought concerning the clinical and pathological features of each patient so that a comparison could be made between the group who survived for more than 20 years without recurrence or metastasis and those who died before this time. The object of the study was to identify those features observable at first presentation that predicted a favourable long term prognosis. In addition, the value of known "short term" prognostic indicators in predicting long term survival was also assessed.
Patients and methods
On reviewing the original histological slides we found that three survivors had had benign lesions (sclerosing papilloma, epithelial hyperplasia, and sclerosing adenosis). They were excluded from the study. We also excluded nine patients with in situ carcinomas. This left a total study population of 227 patients with histologically confirmed invasive breast cancer (tumour node metastasis (TNM) stages 104 of the 173 patients for whom histological data were available) 18 patients (17%) would have received unnecessary treatment.
In contrast, of the 69 patients known to have had unaffected axillary nodes 39 (570%') died in the subsequent 20 years.
Interestingly, five (10%) of the so called "cured group" died of metastases after developing contralateral breast cancer more than 20 years after first treatment. Although there is no firm evidence to support this, many late deaths from breast cancer may possibly be the result of new tumours rather than a late manifestation of slow growing micrometastases.
Our results indicate that, although age, menstrual state, clinical stage, and spread to axillary nodes are of some prognostic value in breast cancer, the present inadequacy of knowledge of the behaviour of the disease makes accurate prediction of which patients will be cured impossible. concentration was raised at 3-92 mmol/I (15-7 mg/100 ml), fell transiently after treatment with intravenous saline, but rose again to 3-66 mmol/l (14-6 mg/100 ml) despite continuous rehydration for 19 days.
Case 2-A 32 year old woman underwent renal transplantation three months before presentation. Radiographs and serum alkaline phosphatase activity showed no evidence of bone disease, but 14 months previously she had received lax-hydroxycholecalciferol for hyperparathyroid bone disease. Renal function was stable (creatinine clearance 38 ml/min), and immunosuppression was maintained with azathioprine and prednisolone. One month after transplantation she developed cough and dyspnoea, subsequently attributed to cytomegalovirus infection, and required assisted ventilation for four weeks. She then developed a generalised grade II limb weakness due to a peripheral motor neuropathy. Power returned gradually over the subsequent two months, but serum calcium concentration rose to mmol/l (14 mg/100 ml) despite adequate hydration and treatment with prednisolone (10 mg daily).
In both patients serum immunoreactive parathyroid hormone was undetectable (<40 pg/ml) and the concentration of 1,25-dihydroxycholecalciferol was low (21 pmol/l (8-2 pg/ml) and 42 pmol/l (16-9 pg/ml) respectively; normal 45-138 pmol/l (18-55 pg/ml)). Both patients had biochemical evidence of increased bone resorption as judged by high ratios of fasting urinary calcium to creatinine concentrations (figure) and of hydroxyproline to creatinine concentrations (374 and 83-3 mmol/mol (434 and 97 mg/g) respectively (normal 10-30 mmol/mol (12-35 mg/g)). Both patients were treated with clodronate and became normocalcaemic within five days (figure). When treatment was stopped after five days in case 2 the hypercalcaemia recurred, but it responded to further treatment. Fasting urinary calcium excretion, initially high in both patients, fell to normal within two weeks after the start of treatment. In case 1 both serum calcium concentration and fasting urinary calcium excretion rose transiently when clodronate was stopped after one month of treatment. Urinary hydroxyproline excretion was initially unchanged but fell gradually to normal after three months in both patients.
Comment
It is not clear whether the increasing mobility of our two patients may in some way have triggered their hypercalcaemia. Serum concentrations of 1,25-dihydroxycholecalciferol were low, suggesting that intestinal absorption of calcium was also low. The undetectable concentrations of immunoreactive parathyroid hormone excluded hyperparathyroidism as a cause for the hypercalcaemia.
Both patients had biochemical evidence of increased bone resorption, and in both creatinine clearance was impaired. Impairment of renal function would not cause, but is likely to contribute to, hypercalcaemia, and in both cases appreciable bone resorption appeared to be the major mechanism for hypercalcaemia. These conclusions are supported by the response of these patients to clodronate. This agent has been previously used in Paget's disease and hypercalcaemic disorders associated with increased bone resorption. 4 The effects of clodronate in immobilisation hypercalcaemia have not been reported previously, although the drug inhibits bone loss after immobilisation in experimental animals and in paraplegia. Plasma calcium concentration and fasting urinary calcium excretion decreased in both our patients, indicating the efficacy of treatment. The diphosphonate etidronate is also effective,5 but its action to
